Increased plasma agmatine levels in patients with schizophrenia

Simple item page
dc.contributor.authorUzbay, İsmail Tayfun
dc.contributor.authorKayır, Hakan
dc.contributor.authorUlusoy, Kemal Gökhan
dc.contributor.buuauthorGöktalay, Gökhan
dc.contributor.buuauthorEker, Salih Saygın
dc.contributor.buuauthorSarandöl, Aslı
dc.contributor.buuauthorOral, Sema
dc.contributor.buuauthorBüyükuysal, Levent
dc.contributor.buuauthorKirli, Selçuk
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Farmakoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı.tr_TR
dc.contributor.researcheridAAH-1448-2021tr_TR
dc.contributor.scopusid6508023759tr_TR
dc.contributor.scopusid14019347700tr_TR
dc.contributor.scopusid14020405100tr_TR
dc.contributor.scopusid6507171811tr_TR
dc.contributor.scopusid14019745700tr_TR
dc.contributor.scopusid55671960400tr_TR
dc.date.accessioned2022-08-17T11:31:09Z
dc.date.available2022-08-17T11:31:09Z
dc.date.issued2013-08
dc.description.abstractAgmatine is an endogenous substance, synthesized from L-arginine, and it is proposed to be a new neurotransmitter. Preclinical studies indicated that agmatine may have an important role in the pathophysiology of schizophrenia. This study was organized to investigate plasma agmatine in patients with schizophrenia and in healthy controls. Eighteen patients with schizophrenia and 19 healthy individuals constituted the subjects. Agmatine levels in the plasma were measured using the HPLC method. The S100B protein level, which is a peripheral biomarker for brain damage, was also measured using the ELISA method. While plasma levels of agmatine in patients with schizophrenia were significantly increased (p < 0.0001) compared to those of healthy individuals (control), there were no significant changes in the levels of S100B protein (p = 0.660). An ROC (receiver operating characteristic) curve analysis revealed that measuring plasma agmatine levels as a clinical diagnostic test would significantly differentiate between patients with schizophrenia and those in the control group (predictive value: 0.969; p < 0.0001). The predictive value of S100B measurements was not statistically significant (p > 0.05). A multiple regression analysis revealed that the age of the patient and the severity of the illness, as indicated by the PANSS score, significantly contributed the plasma agmatine levels in patients with schizophrenia. These results support the hypothesis that an excess agmatine release is important in the development of schizophrenia. The findings also imply that the plasma agmatine level may be a potential biomarker of schizophrenia.en_US
dc.identifier.citationUzbay, T. vd.(2013). "Increased plasma agmatine levels in patients with schizophrenia". Journal of Psychiatric Research, 47(8), 1054-1060.en_US
dc.identifier.endpage1060tr_TR
dc.identifier.issn0022-3956
dc.identifier.issn1879-1379
dc.identifier.issue8tr_TR
dc.identifier.pubmed23664672tr_TR
dc.identifier.scopus2-s2.0-84878648177tr_TR
dc.identifier.startpage1054tr_TR
dc.identifier.urihttps://doi.org/10.1016/j.jpsychires.2013.04.004
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/23664672/
dc.identifier.urihttp://hdl.handle.net/11452/28232
dc.identifier.volume47tr_TR
dc.identifier.wos000321073500010tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Scienceen_US
dc.relation.collaborationYurt içitr_TR
dc.relation.journalJournal of Psychiatric Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.relation.tubitakSBAG-HD-110S236tr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPsychiatryen_US
dc.subjectAgmatineen_US
dc.subjectPolyaminesen_US
dc.subjectS100Ben_US
dc.subjectSchizophreniaen_US
dc.subjectBiomarkeren_US
dc.subjectPrepulse inhibition deficitsen_US
dc.subjectNeurotrophic factoren_US
dc.subjectProtein s100ben_US
dc.subjectBlood-levelsen_US
dc.subjectBrainen_US
dc.subjectMarkeren_US
dc.subjectSerumen_US
dc.subjectPolyaminesen_US
dc.subjectHippocampalen_US
dc.subjectCortexen_US
dc.subject.emtreeAgmatineen_US
dc.subject.emtreeBiological markeren_US
dc.subject.emtreeProtein S100Ben_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeConcentration (parameters)en_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDisease durationen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHigh performance liquid chromatographyen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreePositive and Negative Syndrome Scaleen_US
dc.subject.emtreePredictive valueen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeSchizophreniaen_US
dc.subject.scopusAgmatine; 2-(2-Benzofuranyl)-2-Imidazoline; 2 (2 Imidazolin 2 Yl)Quinolineen_US
dc.subject.wosPsychiatryen_US
dc.titleIncreased plasma agmatine levels in patients with schizophreniaen_US
dc.typeArticle
dc.wos.quartileQ1en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus